Skip to main content
Explore URMC




David TophamDavid Topham, Ph.D.

Director and PI
Professor of Microbiology and Immunology
David H Smith Center for Vaccine Biology and Immunology

Antigenic evolution and immunity to influenza.

Why does the influenza vaccine fail? In spite of substantial efforts to vaccinate, influenza epidemics remain a major public health threat. In the US, the currently licensed vaccines are very safe, but only partially effective at protecting from infection.  Though efficacy rates vary with age of the subjects and virus strains, estimates of protection range from 10-70%.  As our abilities to study influenza viruses at the molecular level increase, and the costs to do so decrease, there are more reports of a significant degree of sequence diversity in the viruses that circulate seasonally.  This raises the possibility that some of the vaccine failures may be due to antigenic drift in the viruses.  Unfortunately, there are few (to no) studies that have assayed the virus sequences and antigenicity, and the specificity or function of the antibodies and memory B cells present in the subject who is infected. As part of our surveillance activities, we will collect and analyze the viruses causing infections and match these to the individual’s antibody and B cell responses present before infection or at the time illness begins.  We will also study the impact of infections versus vaccination on the responding B cell and immunoglobulin (Ig) specificity and function, including development of memory.  We will also use in vitro approaches that drive antigenic drift in prototypical seasonal influenza viruses to better understand how differences in immune profiles affect virus evolution.  To take this further, we propose to use the information from circulating viruses and antibody/B cell specificity to develop computational tools that analyze and predict human immune responses to influenza. We will use these models to both better understand human immunity to flu, but to also simulate how prior immunity affects immune responses to various immunization strategies.  Our goal is to develop approaches to immunization that produce more broadly cross-reactive and even “universal” immunity to flu. To accomplish these lofty goals, we have assembled a team of the very best immunologists, virologists, computational biologists, and clinical investigators who will work together on this project using cutting edge technologies. These studies have the potential to change the way we think about influenza immunity and vaccination, and create a better understanding of immune protection and virus selection.

Andrea SantAndrea J. Sant, Ph.D.

Professor of Microbiology and Immunology
David H Smith Center for Vaccine Biology and Immunology
Immunodominance of CD4 T cell responses to influenza virus

Dr. Sant received her Ph.D. in Immunogenetics from Washington University in St. Louis in 1985. She currently Professor of Microbiology and Immunology at the University of Rochester. The research in Dr. Sant’s laboratory centers around the molecular events that regulate MHC class II- restricted antigen presentation of influenza proteins by antigen presenting cells (APC) and CD4 T cell recruitment in vivo. Dr. Sant will lead project 3, focused on the CD4 response to infection and vaccination, and the potential impact of CD4 peptide specificity on the development of B cell responses specifically to the HA protein.

Patrick C. WilsonPatrick C. Wilson, Ph.D.

Dr. Wilson received his Ph.D. in Immunology from the University of Texas Southwestern Medical Center in 2000, and post- doctoral training in the Nussenzweig lab at The Rockefeller University in New York City. He currently serves as Associate Professor with tenure in the Department of Medicine/Rheumatology,at the University of Chicago.

Dr. Wilson’s interests include the development of technology to clone recombinant monoclonal antibodies from discreet populations of B cells. Dr. Wilson will lead Project 2 focused on the B cell response to infection, as well as providing monoclonal antibodies he has, and cloning additional human antibodies specific for influenza HA and NA glycoproteins.

Hana Golding, Ph.D.Hana Golding, Ph.D.

Dr. Golding will assist with studies conducted under project 1. Dr. Golding received her Ph.D. in Immunology from Oregon Health Sciences University in 1981, and completed post-graduate work as a Visiting Fellow under Dr. Alfred Singer in 1985 at the Immunology Branch, NCI, NIH, and then as a Visiting Associate in the same branch under Dr. Dinah Singer in 1987. She joined the Food and Drug Administration in 1989, and since 1993 she has served as Chief of the Laboratory of Retrovirus Research in the Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA). She will lead the experiments in Aims 1 and 2 of Project 1 to perform Gene Fragment Phage Display Library (GFPDL) studies of antibody specificity, a technique that she pioneered for use in influenza.

Surender Khurana, Ph.D.Surender Khurana, Ph.D.

Dr. Surender Khurana will assist in the conduct of studies in project 1. Dr. Khurana received his Ph.D. in Biochemistry in 2002 from Delhi University, India. He has been at the Food and Drug Administration since 2002, where he currently serves as Staff Scientist in the Division of Viral Products, Center for Biologics Evaluation and Research (CBEM). His research interests are focused on developing new molecular tools for better understanding of how different vaccine modalities and novel adjuvants improve protective immunity against influenza. Dr. Khurana developed the Surface Plasmon Resonance (SPR) assays which will be used in project 1.

Luis Martínez-SobridoLuis Martínez-Sobrido, Ph.D.

Dr. Martínez-Sobrido received his Ph.D. in Virology and Molecular Biology in 2000 from the Instituto de Salud Carlos III and completed Postdoctoral training at Mount Sinai School of Medicine. He is currently Assistant Professor. He is interested in the use of plasmid-based reverse genetics techniques to rescue recombinant influenza viruses. He will construct recombinant single cycle influenza viruses for assessment of immunity.

Mark Sangster, Ph.D.Mark Y. Sangster, Ph.D.

Research Professor
David H Smith Center for Vaccine Biology and Immunology

Dr. Sangster received his Ph.D. in Virology/Genetics from the University of Western Australia in 1991. He then completed postdoctoral work  in Immunology at St. Jude’s Children’s Research Hospital. Dr. Sangster is an expert in the analysis of B cell responses to infection and vaccination. His major interests have been mucosal aspects of B cell responses in the respiratory tract and the nature of virus-specific B cell memory. He will perform studies of mucosal antibody and B cell responses, and B cell memory.

Jeanne Holden-Wiltse, M.P.H.Jeanne Holden-Wiltse, M.P.H.

Ms. Holden-Wiltse received her MPH from University of Michigan School of Public Health in 1991, and has over 17 years of experience in biostatistical support having held positions in industry, government, not-for-profit organizations and academia. Ms. Holden-Wiltse will act as Co-Leader of the Data Management, Bioinformatics and Biostatistics Core.




ArnoldMontoArnold Monto, M.D.

Arnold S. Monto, MD is the Thomas Francis Jr. Collegiate Professor of Public Health at the Department of Epidemiology, University of Michigan School of Public Health.  Respiratory infections in tropical and temperate regions have been a major interest. He led the studies of respiratory illnesses in Tecumseh, MI, a landmark investigation of infection in the community   Dr. Monto had been involved in assessing the efficacy of various influenza vaccines and of neuraminidase inhibitors and other compounds in prophylaxis and therapy of influenza.  He now heads observational studies of effectiveness of influenza vaccines and household studies of respiratory viral infections, including respiratory syncytial virus (RSV). He has been a member of the National Allergy and Infectious Disease Advisory Council of the US National Institutes of Health and is now a member of the FDA’s Vaccines and Related Biologicals Advisory Committee (VRBPAC).  He is a past president of the American Epidemiological Society, the 2009 recipient of the Alexander Fleming Award of the Infectious Diseases Society of America for lifetime achievement and the 2012 recipient of the Charles Merieux award of the National Foundation for Infectious Diseases. 


Joshua Petrie, Ph. D.

Research Investigator

University of Michigan 

Joshua G. Petrie is a Research Investigator in the Department of Epidemiology at the University of Michigan School of Public Health.  He received his BS (2004) in Biology from the University of Michigan, and his MPH (2008) and PhD (2016) in Epidemiology from the University of Michigan School of Public Health. Dr. Petrie’s research interests include the epidemiology and transmission of respiratory viruses, influenza vaccine effectiveness, and serologic correlates of protection. 

ScottHensleyScott Hensley, Ph. D. 

Associate Professor

University of Pennsylvania

He received his B.A. in Biology from the University of Delaware in 2000 and his Ph.D. in Cell and Molecular Biology from the University of Pennsylvania in 2006.  He completed a postdoctoral fellowship at the National Institute of Health from 2007-2010 and was an Assistant Professor at the Wistar Institute from 2010-2016.  The Hensley laboratory studies mechanisms that promote antigenic drift of influenza viruses and factors that influence influenza vaccine responsiveness.


SarahCobeySarah Cobey, Ph. D.

Assistant Professor in Ecology & Evolution and the Committee on Microbiology

University of Chicago

Dr. Cobey computationally models the evolution of influenza and the evolution of antibody repertoires. She uses diverse approaches that range from phylogenetics and population genetics to longitudinal and population-level dynamical models. She is working with Scott Hensley to use cross-sectional data on antibody repertoires to improve forecasting of influenza for vaccine strain selection. Her other work investigates immunodominance and original antigenic sin. Dr. Cobey received a PhD in Ecology & Evolution from the University of Michigan in 2009 and completed a postdoctoral fellowship at the Harvard School of Public Health. 

Angela BrancheAngela Branche, M.D

Dr. Branche is an assistant professor at the University of Rochester, School of Medicine. She currently has a clinical inpatient practice comprised of both general infectious diseases and HIV medicine patients. Dr. Branche is also a New York State designated HIV/AIDS provider and has a practice comprised of adult patients ages 18 and older at the URMC HIV Clinic.

The focus of her research has been clinical and translation research in the field of respiratory infections in adults. Dr. Branche received her Bachelor of Arts degree in Biology at the University of Pennsylvania and Doctorate in Medicine at American University of the Caribbean. She completed residency in Internal Medicine at NYU Lutheran in Brooklyn, NY and infectious disease fellowship at the University of Rochester.  During her training years at the University of Rochester her focus in research involved the use of viral diagnostics and serum biomarkers to investigate acute viral respiratory illnesses in adults. She is currently a clinical investigator in the National Institute of Allergy and Infectious Diseases Respiratory Pathogen Research Center at the University of Rochester and her current research activities have been expanded to include surveillance studies for bacterial pathogens including the presence of nasopharygneal colonization with Streptococcus pneumoniae in older and the clinical and biological impact of colonization in this population. She has experience in the development and performance of diagnostic PCR assays for respiratory viruses including influenza, respiratory syncytial virus, coronaviruses and human metapneumovirus as well as bacterial pathogens such as Streptococcus pneumoniae. Dr. Branche has published several peer-reviewed articles, reviews and book chapters related to respiratory viral pathogens in adults. 

Juliet MorrisonJuliet Morrison, Ph. D

Associate Research Scientist

Columbia University 

In my current position as a faculty member in the Center for Infection and Immunity (CII) at Columbia University, I lead collaborative influenza research projects under a NIH subcontract while conducting systems-level research pertaining to emerging and re-emerging pathogens. My specialty is combining computational analysis, immunological and virological methods to address questions at the host-pathogen interface. I have spent the last 14 years studying innate immune responses to viral pathogens such as dengue virus, rhinovirus, poliovirus, yellow fever virus and influenza virus. During my graduate studies at Columbia University, I discovered that a viral protease facilitated poliovirus and rhinovirus interferon resistance. During my postdoctoral training at Mount Sinai School of Medicine, I discovered and characterized two novel and disparate mechanisms whereby the NS5 proteins of dengue virus and yellow fever virus inhibit interferon signaling to enhance viral replication and pathogenesis. These discoveries earned my research a PLOS Pathogens cover, an editorial in Cell Host & Microbe, and a vaccine patent. At the University of Washington, I showed that influenza disease severity correlates with host transcriptional signatures of increased cytokine production, decreased coagulation signaling, and decreased lipid metabolism. This research was featured in Microsoft’s #DoMore campaign (June 2015) and in American Society for Microbiology’s Microbe Magazine (August 2014).

My current focus is computationally identifying and experimentally validating immune cell populations and host pathways and that can be targeted therapeutically to ameliorate severe viral disease. A major interest of mine is using tissue deconvolution algorithms and immunological tools to study the dynamics of lung immune cell populations during influenza virus infections, and spleen and liver immune cell populations during dengue virus infections. My goal is to translate these findings into host-targeted influenza and flavivirus therapeutics.

Jennifer NayakJennifer Nayak, M. D.

Dr. Nayak received her M.D. from the State University of New York at Buffalo in 2004 and subsequently completed residency training in Pediatrics and a fellowship in Pediatric Infectious Diseases at the University of Rochester.  She is currently an Assistant Professor in the Department of Pediatrics.  The research in Dr. Nayak’s laboratory is focused on understanding how a child’s early exposure to influenza shapes immunity and poises the immune system to respond to subsequent influenza challenge.  While some children continue to have their first exposure to influenza through infection, high influenza morbidity in infants and children has led to a universal recommendation for inactivated influenza vaccination starting at 6 months of age, with children >24 months able to receive live attenuated vaccine.  Despite this, little is known about how these different modes of priming alter the development of influenza-specific immunologic memory.  To better understand these issues, Dr. Nayak is conducting a clinical study to determine how the functional potential of the anti-influenza immune response in early childhood is initially shaped by infection versus vaccination and the consequences this has on the subsequent development of long term anti-influenza immunity. 

John Treanor, MDJohn Treanor, M.D.

Professor Emeritus of Medicine and Microbiology and Immunology
Department of Medicine
Division of Infectious Diseases
Human immune responses to influenza virus, and clinical vaccine trials

John Treanor, M.D. is the Founding Director of the New York Center of Excellence and former leader of the clinical core. He made the transition to professor emeritus and ended a formal role in the NYICE as of January 2018. Dr. Treanor received his medical degree in 1979 from the University of Rochester and performed a fellowship in Infectious Diseases at the University of Rochester. Dr. Treanor has a nearly 40 year interest in clinical research on influenza and vaccine development, and has been particularly involved in seminal studies of live attenuated vaccines for seasonal and pandemic influenza, as well as clinical studies of antiviral medications. While no longer in a formal role for the NYICE, Dr. Treanor will continue to be involved in the activities of the clinical core, mentoring of faculty, and consulting on studies to assess the immune response to infection and vaccination, and assessing population immunity to seasonal and pandemic threat viruses.

Doreen M. Francis, R.N., C.C.R.CDoreen M. Francis, R.N., C.C.R.C

Ms. Francis received her R.N. in 1973 from the Highland Hospital School of Nursing. She currently serves as Research Administrator and Coordinator for the Vaccine Research Unit in the Infectious Diseases Division at the University of Rochester. Ms. Francis is a highly experienced clinical research coordinator, and she will oversee regulatory and operational aspects of clinical research conducted by NYICE.

Donna Neu, PMPDonna Neu, PMP

Ms. Neu received her B.A. in Computer Science from the State University of New York at Oswego in 1986, and her PMP from the Project Management Institute in 2005. She is currently Project Manager of the New York Influenza Center of Excellence, and the Respiratory Pathogens Research Center at UR. As Project Manager, Ms. Neu will oversee day to day operations of NYICE and coordinate interactions between other CEIRS centers, NYICE and contract operations.


Jaycee BristolJaycee Budd

Ms Budd graduated from SUNY Brockport in 2014 with bachelors degrees in healthcare administration and psychology. She is currently Project Manager Assistant of the New York Influenza Center of Excellence, and the Respiratory Pathogens Research Center at UR. As Assistant Project Manager, Ms Budd assists in overseeing day to day operations of the RPRC and NYICE as well as putting together reports and meeting minutes to send to the National Institute of Health regarding the NYICE and RPRC contracts.